A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

Even more encouragingly, most people maintained the weight loss for the entire three-year study. “Our long-term analysis of tirzepatide establishes that clinically relevant weight loss can be ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes ...

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1, receptor agonist, has shown promise in promoting weight loss and improving ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the mechanisms of action of tirzepatide – a drug known as Zepbound™ – on weight ...

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...